Indivior (NASDAQ:INDV) CFO Ryan Preblick Sells 36,000 Shares

Indivior PLC (NASDAQ:INDV) CFO Ryan Preblick sold 36,000 shares of the firm’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $37.70, for a total value of $1,357,200.00. Following the completion of the sale, the chief financial officer directly owned 284,751 shares in the company, valued at approximately $10,735,112.70. This trade represents a 11.22% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Indivior Trading Down 0.4%

Shares of NASDAQ INDV opened at $38.09 on Thursday. Indivior PLC has a 12-month low of $13.45 and a 12-month high of $41.00. The company has a market cap of $4.64 billion, a price-to-earnings ratio of 19.53 and a beta of 0.88. The stock’s 50 day simple moving average is $35.13 and its 200 day simple moving average is $34.24.

Indivior (NASDAQ:INDV) last posted its earnings results on Tuesday, March 31st. The company reported $0.96 EPS for the quarter. Indivior had a negative return on equity of 219.26% and a net margin of 19.44%.The firm had revenue of $317.00 million for the quarter. As a group, equities analysts forecast that Indivior PLC will post 4.05 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on INDV shares. Zacks Research raised Indivior from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 16th. Weiss Ratings downgraded Indivior from a “hold (c+)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $39.33.

Hedge Funds Weigh In On Indivior

A number of hedge funds have recently modified their holdings of INDV. Oaktree Capital Management LP grew its holdings in shares of Indivior by 2,241.6% in the 3rd quarter. Oaktree Capital Management LP now owns 257,785,398 shares of the company’s stock worth $6,215,206,000 after acquiring an additional 246,776,273 shares during the last quarter. Divisadero Street Capital Management LP grew its holdings in shares of Indivior by 2,372.5% in the 3rd quarter. Divisadero Street Capital Management LP now owns 3,362,605 shares of the company’s stock worth $81,072,000 after acquiring an additional 3,226,605 shares during the last quarter. Fuller & Thaler Asset Management Inc. grew its holdings in shares of Indivior by 101.0% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 6,371,534 shares of the company’s stock worth $228,611,000 after acquiring an additional 3,201,639 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of Indivior in the 4th quarter worth $82,687,000. Finally, Vanguard Group Inc. grew its holdings in shares of Indivior by 57.9% in the 4th quarter. Vanguard Group Inc. now owns 5,473,891 shares of the company’s stock worth $196,403,000 after acquiring an additional 2,008,078 shares during the last quarter. 60.33% of the stock is currently owned by institutional investors and hedge funds.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.